BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

PolyRemedy Hires Gary Coughlen as CFO


10/28/2008 7:48:23 AM

MOUNTAIN VIEW, Calif., Oct. 28 /PRNewswire/ -- PolyRemedy, Inc., a manufacturer of point-of-care robotic systems for the fabrication and tracking of customized, nano-material-based wound treatments, has hired Gary Coughlen to serve as the Company's chief financial officer. Coughlen joined the PolyRemedy management team on October 14, 2008, and reports directly to the Company's president and chief executive officer Dan Eckert.

"We are pleased to have Gary on board. Gary is a seasoned professional with more than 20 years of experience in finance, much of it in the medical device setting," Eckert says. "As we prepare to launch revolutionary technology to the wound care market, his experience and proven understanding of the challenges and opportunities facing a rapidly growing medical device company will be a great asset to our team."

As CFO, Coughlen will be responsible for all aspects of PolyRemedy's finance function, including accounting, financial planning and analysis, and internal policy development. In addition, he will oversee other important departments, including facilities, legal, intellectual property and human resources.

"PolyRemedy is an exciting company in an exciting time. I look forward to doing my part in helping the company successfully transform from a start-up, R&D focus to a world class leader offering innovative solutions to the wound care market," Coughlen says.

Coughlen most recently served as CFO and board secretary for Refractec, Inc., a vision technology firm based in Irvine, Ca. While there, he helped raise $42 million in equity capital and $8 million in non-bank debt financing, and he managed the company banking relationship. Coughlen oversaw the company's growth from 3 to 75 employees, and helped transition the company from its R&D stages to commercialization of its product after FDA approval. In addition, he oversaw many legal functions, including patent filing and protection, and established internal departments and policies.

Prior to Refractec, Coughlen served in financial leadership roles at Scieran Technologies, Inc., Laguna Hills, Calif., Precision Capital, Walnut Creek, Calif., and Sierra Capital, Inc., San Francisco. Coughlen also worked in various positions at Concord Assets Group, Boca Raton, Fla., and Security Properties, Inc., and Pricerwaterhouse, both in Seattle, Wash.

Coughlen holds a bachelor's degree in business/accounting from the University of Washington and an MBA from University of California, Berkeley. He is also a certified public accountant.

About PolyRemedy

PolyRemedy, based in Mountain View, Calif., manufactures robotic systems for the fabrication of nano- and micro-fiber wound treatments, on demand and at the point of care. The innovative PolyRemedy system produces customized wound dressings within minutes, measured to fit the wound size and shape and fabricated with the precise material composition necessary to optimally treat the wound. The system also captures and monitors important wound treatment data with the potential to help evaluate costs, refine clinical protocols, and demonstrate evidence-based improvements in wound management.

CONTACT: Kristi Ashton, Director of Product Marketing of PolyRemedy, Inc.,
+1-650-960-2404, ext. 146, kristia@polyremedy.com

Web site: http://www.polyremedy.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->